Recent sarcopenia definitions - prevalence, agreement and mortality associations among men: findings from population-based cohorts
Recent sarcopenia definitions - prevalence, agreement and mortality associations among men: findings from population-based cohorts
Background: The 2019 European Working Group on Sarcopenia in Older People (EWGSOP2) and the Sarcopenia Definitions and Outcomes Consortium (SDOC) have recently proposed sarcopenia definitions. However, comparisons of the performance of these approaches in terms of thresholds employed, concordance in individuals and prediction of important health-related outcomes such as death are limited. We addressed this in a large multinational assembly of cohort studies that included information on lean mass, muscle strength, physical performance and health outcomes. Methods: White men from the Health Aging and Body Composition (Health ABC) Study, Osteoporotic Fractures in Men (MrOS) Study cohorts (Sweden, USA), the Hertfordshire Cohort Study (HCS) and the Sarcopenia and Physical impairment with advancing Age (SarcoPhAge) Study were analysed. Appendicular lean mass (ALM) was ascertained using DXA; muscle strength by grip dynamometry; and usual gait speed over courses of 2.4–6 m. Deaths were recorded and verified. Definitions of sarcopenia were as follows: EWGSOP2 (grip strength <27 kg and ALM index <7.0 kg/m
2), SDOC (grip strength <35.5 kg and gait speed <0.8 m/s) and Modified SDOC (grip strength <35.5 kg and gait speed <1.0 m/s). Cohen's kappa statistic was used to assess agreement between original definitions (EWGSOP2 and SDOC). Presence versus absence of sarcopenia according to each definition in relation to mortality risk was examined using Cox regression with adjustment for age and weight; estimates were combined across cohorts using random-effects meta-analysis. Results: Mean (SD) age of participants (n = 9170) was 74.3 (4.9) years; 5929 participants died during a mean (SD) follow-up of 12.1 (5.5) years. The proportion with sarcopenia according to each definition was EWGSOP2 (1.1%), SDOC (1.7%) and Modified SDOC (5.3%). Agreement was weak between EWGSOP2 and SDOC (κ = 0.17). Pooled hazard ratios (95% CI) for mortality for presence versus absence of each definition were EWGSOP2 [1.76 (1.42, 2.18), I
2: 0.0%]; SDOC [2.75 (2.28, 3.31), I
2: 0.0%]; and Modified SDOC [1.93 (1.54, 2.41), I
2: 58.3%]. Conclusions: There was low prevalence and poor agreement among recent sarcopenia definitions in community-dwelling cohorts of older white men. All indices of sarcopenia were associated with mortality. The strong relationship between sarcopenia and mortality, regardless of the definition, illustrates that identification of appropriate management and lifecourse intervention strategies for this condition is of paramount importance.
Ageing, Epidemiology, Mortality, Prevalence, Sarcopenia
565-575
Westbury, Leo
5ed45df3-3df7-4bf9-bbad-07b63cd4b281
Beaudart, Charlotte
bdc9da98-791a-474b-9745-be0695a4d8a9
Bruyère, Olivier
ba727e54-ca17-4fa8-be3d-4729fb4b8c0d
Cauley, Jane A.
fbc60b0d-09fd-445d-83df-b61521bcf775
Cawthon, Peggy M.
135b12d2-41a8-4a6d-bd42-a484b930b286
Cruz-Jentoft, Alfonso Jose
bd1054e6-e6b7-4f15-856b-a3de3887064d
Curtis, Elizabeth
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Ensrud, Kristine
827f9bd5-65d5-4382-a4bd-081d81f89ae6
Fielding, Roger A.
36b26592-ce59-4443-ab26-185919da78c0
Johansson, Helena
04f12338-4dd1-437b-b9bc-e0884130c215
Kanis, John A.
f1621d8d-8afb-4d97-9679-2165d88a344d
Karlsson, Magnus K.
ff2ab335-2e30-4749-88ee-9048fa1dbd7e
Lane, Nancy E.
3bf8d93e-2d26-4bb3-a209-4eb3f16d774f
Lengelé, Laetitia
c66b5c66-530b-4e75-adba-971fa55bc168
Lorentzon, Mattias
9d78ed25-2b0c-46c5-a2db-a8b246af0956
McCloskey, Eugene
6d3df4aa-b438-4a83-bd06-06b6cbe3980f
Mellström, Dan
178bfc48-331d-4dec-bda0-45e72d303f6e
Newman, Anne B.
c20887ec-62be-4736-b599-256e76ca00d5
Ohlsson, Claes
98168752-6ef1-40c6-b873-9361cc99358b
Orwoll, Eric
65da4e11-2b2e-44fa-9a56-f60aac992f19
Reginster, Jean Yves
33684a35-87f7-4b8d-bb91-4da2b809f855
Ribom, Eva
02f2cfbb-2b7a-4b07-84d8-9179611f55db
Rosengren, Bjorn E.
3434a7e2-291f-44cd-bd8a-7dde0a13b0ab
Schousboe, John T.
f2b87d0a-88cb-462f-bc70-df2d984c9d1e
Shiroma, Eric J.
6ddbea5d-7eb6-4a28-b345-eb413a442607
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
February 2023
Westbury, Leo
5ed45df3-3df7-4bf9-bbad-07b63cd4b281
Beaudart, Charlotte
bdc9da98-791a-474b-9745-be0695a4d8a9
Bruyère, Olivier
ba727e54-ca17-4fa8-be3d-4729fb4b8c0d
Cauley, Jane A.
fbc60b0d-09fd-445d-83df-b61521bcf775
Cawthon, Peggy M.
135b12d2-41a8-4a6d-bd42-a484b930b286
Cruz-Jentoft, Alfonso Jose
bd1054e6-e6b7-4f15-856b-a3de3887064d
Curtis, Elizabeth
12aba0c3-1e9e-49ef-a7e9-3247e649cdd6
Ensrud, Kristine
827f9bd5-65d5-4382-a4bd-081d81f89ae6
Fielding, Roger A.
36b26592-ce59-4443-ab26-185919da78c0
Johansson, Helena
04f12338-4dd1-437b-b9bc-e0884130c215
Kanis, John A.
f1621d8d-8afb-4d97-9679-2165d88a344d
Karlsson, Magnus K.
ff2ab335-2e30-4749-88ee-9048fa1dbd7e
Lane, Nancy E.
3bf8d93e-2d26-4bb3-a209-4eb3f16d774f
Lengelé, Laetitia
c66b5c66-530b-4e75-adba-971fa55bc168
Lorentzon, Mattias
9d78ed25-2b0c-46c5-a2db-a8b246af0956
McCloskey, Eugene
6d3df4aa-b438-4a83-bd06-06b6cbe3980f
Mellström, Dan
178bfc48-331d-4dec-bda0-45e72d303f6e
Newman, Anne B.
c20887ec-62be-4736-b599-256e76ca00d5
Ohlsson, Claes
98168752-6ef1-40c6-b873-9361cc99358b
Orwoll, Eric
65da4e11-2b2e-44fa-9a56-f60aac992f19
Reginster, Jean Yves
33684a35-87f7-4b8d-bb91-4da2b809f855
Ribom, Eva
02f2cfbb-2b7a-4b07-84d8-9179611f55db
Rosengren, Bjorn E.
3434a7e2-291f-44cd-bd8a-7dde0a13b0ab
Schousboe, John T.
f2b87d0a-88cb-462f-bc70-df2d984c9d1e
Shiroma, Eric J.
6ddbea5d-7eb6-4a28-b345-eb413a442607
Harvey, Nicholas
ce487fb4-d360-4aac-9d17-9466d6cba145
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Westbury, Leo, Beaudart, Charlotte, Bruyère, Olivier, Cauley, Jane A., Cawthon, Peggy M., Cruz-Jentoft, Alfonso Jose, Curtis, Elizabeth, Ensrud, Kristine, Fielding, Roger A., Johansson, Helena, Kanis, John A., Karlsson, Magnus K., Lane, Nancy E., Lengelé, Laetitia, Lorentzon, Mattias, McCloskey, Eugene, Mellström, Dan, Newman, Anne B., Ohlsson, Claes, Orwoll, Eric, Reginster, Jean Yves, Ribom, Eva, Rosengren, Bjorn E., Schousboe, John T., Shiroma, Eric J., Harvey, Nicholas, Dennison, Elaine and Cooper, Cyrus
(2023)
Recent sarcopenia definitions - prevalence, agreement and mortality associations among men: findings from population-based cohorts.
Journal of Cachexia, Sarcopenia and Muscle, 14 (1), .
(doi:10.1002/jcsm.13160).
Abstract
Background: The 2019 European Working Group on Sarcopenia in Older People (EWGSOP2) and the Sarcopenia Definitions and Outcomes Consortium (SDOC) have recently proposed sarcopenia definitions. However, comparisons of the performance of these approaches in terms of thresholds employed, concordance in individuals and prediction of important health-related outcomes such as death are limited. We addressed this in a large multinational assembly of cohort studies that included information on lean mass, muscle strength, physical performance and health outcomes. Methods: White men from the Health Aging and Body Composition (Health ABC) Study, Osteoporotic Fractures in Men (MrOS) Study cohorts (Sweden, USA), the Hertfordshire Cohort Study (HCS) and the Sarcopenia and Physical impairment with advancing Age (SarcoPhAge) Study were analysed. Appendicular lean mass (ALM) was ascertained using DXA; muscle strength by grip dynamometry; and usual gait speed over courses of 2.4–6 m. Deaths were recorded and verified. Definitions of sarcopenia were as follows: EWGSOP2 (grip strength <27 kg and ALM index <7.0 kg/m
2), SDOC (grip strength <35.5 kg and gait speed <0.8 m/s) and Modified SDOC (grip strength <35.5 kg and gait speed <1.0 m/s). Cohen's kappa statistic was used to assess agreement between original definitions (EWGSOP2 and SDOC). Presence versus absence of sarcopenia according to each definition in relation to mortality risk was examined using Cox regression with adjustment for age and weight; estimates were combined across cohorts using random-effects meta-analysis. Results: Mean (SD) age of participants (n = 9170) was 74.3 (4.9) years; 5929 participants died during a mean (SD) follow-up of 12.1 (5.5) years. The proportion with sarcopenia according to each definition was EWGSOP2 (1.1%), SDOC (1.7%) and Modified SDOC (5.3%). Agreement was weak between EWGSOP2 and SDOC (κ = 0.17). Pooled hazard ratios (95% CI) for mortality for presence versus absence of each definition were EWGSOP2 [1.76 (1.42, 2.18), I
2: 0.0%]; SDOC [2.75 (2.28, 3.31), I
2: 0.0%]; and Modified SDOC [1.93 (1.54, 2.41), I
2: 58.3%]. Conclusions: There was low prevalence and poor agreement among recent sarcopenia definitions in community-dwelling cohorts of older white men. All indices of sarcopenia were associated with mortality. The strong relationship between sarcopenia and mortality, regardless of the definition, illustrates that identification of appropriate management and lifecourse intervention strategies for this condition is of paramount importance.
Text
Accepted manuscript (sarc prev agree and mortality)
- Accepted Manuscript
Text
J cachexia sarcopenia muscle - 2023 - Westbury - Recent sarcopenia definitions prevalence agreement and mortality
- Version of Record
More information
Accepted/In Press date: 25 November 2022
e-pub ahead of print date: 5 January 2023
Published date: February 2023
Additional Information:
Funding Information:
The Health, Aging and Body Composition Study was supported by the National Institute on Aging (NIA) grants (R01AG027017, P30AG024827, T32AG021885 and K07AG033174); the Intramural Research Program of the National Institutes of Health (N01AG62101, N01AG62103, N01AG62106 and R01AG028050); and a National Institute of Nursing Research grant (R01NR012459). The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; U01AR066160), the National Center for Advancing Translational Sciences (NCATS; UL1TR000128) and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160 and UL1 TR000128. MrOS Sweden is supported by the Swedish Research Council, ALF/LUA research grants in Gothenburg, ALF, Region Skane (FoUU), Skåne University Hospital Foundation and the King Gustav V and Queen Victoria Frimurarestiftelse Research Foundation. The Hertfordshire Cohort Study was supported by the Medical Research Council University Unit Partnership grant number MRC_MC_UP_A620_1014. Roger Fielding's participation was supported by the U.S. Department of Agriculture (USDA), under agreement no. 58-1950-4-003 any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA. Cyrus Cooper, Elaine Dennison, Nicholas Harvey, Elizabeth Curtis and Leo Westbury are supported by the UK Medical Research Council (MC_PC_21003; MC_PC_21001). The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.33 All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All participants provided informed consent prior to their inclusion in the study. The authors thank the study participants as well as members of the scientific and data collection teams.
Funding Information:
Cyrus Cooper reports personal fees (outside the submitted work) from Amgen, Danone, Eli Lilly, GSK, Kyowa Kirin, Medtronic, Merck, Nestle, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB. Elaine Dennison has received lecture fees and honoraria from UCB, Pfizer, Lilly and Viatris outside of the submitted work. Nicholas Harvey reports consultancy, lecture fees and honoraria (outside the submitted work) from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma. Roger Fielding reports grants from the National Institutes of Health (National Institute on Aging) and the USDA, during the conduct of the study; grants, personal fees and other from Axcella Health; other from Inside Tracker; grants and personal fees from Biophytis; grants and personal fees from Astellas; personal fees from Pfizer; personal fees from Reneo; personal fees from Cytokinetics; personal fees from Amazentis; grants and personal fees from Nestle; and personal fees from Glaxo Smith Kline, outside the submitted work. Jean‐Yves Reginster declares grant support from industry through institution (IBSA‐Genevrier, Mylan, CNIEL, Radius Health, TRB), lecture fees when speaking at the invitation of sponsor [IBSA‐Genevrier, Mylan, CNIEL, Dairy Research Council (DRC), Nutricia, Danone, Agnovos] and consulting fees or paid advisory boards (IBSA‐Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvenate Biomed, Samumed, Teva, Theramex, Pfizer, Mithra Pharmaceuticals). The remaining authors declare that they have no conflicts of interest.
Funding Information:
The Health, Aging and Body Composition Study was supported by the National Institute on Aging (NIA) grants (R01AG027017, P30AG024827, T32AG021885 and K07AG033174); the Intramural Research Program of the National Institutes of Health (N01AG62101, N01AG62103, N01AG62106 and R01AG028050); and a National Institute of Nursing Research grant (R01NR012459). The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; U01AR066160), the National Center for Advancing Translational Sciences (NCATS; UL1TR000128) and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160 and UL1 TR000128. MrOS Sweden is supported by the Swedish Research Council, ALF/LUA research grants in Gothenburg, ALF, Region Skane (FoUU), Skåne University Hospital Foundation and the King Gustav V and Queen Victoria Frimurarestiftelse Research Foundation. The Hertfordshire Cohort Study was supported by the Medical Research Council University Unit Partnership grant number MRC_MC_UP_A620_1014. Roger Fielding's participation was supported by the U.S. Department of Agriculture (USDA), under agreement no. 58‐1950‐4‐003 any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA. Cyrus Cooper, Elaine Dennison, Nicholas Harvey, Elizabeth Curtis and Leo Westbury are supported by the UK Medical Research Council (MC_PC_21003; MC_PC_21001).
Publisher Copyright:
© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Keywords:
Ageing, Epidemiology, Mortality, Prevalence, Sarcopenia
Identifiers
Local EPrints ID: 473276
URI: http://eprints.soton.ac.uk/id/eprint/473276
ISSN: 2190-5991
PURE UUID: a3d98805-1ca3-4bc4-aef4-cb9106600bba
Catalogue record
Date deposited: 13 Jan 2023 17:39
Last modified: 18 Mar 2024 03:38
Export record
Altmetrics
Contributors
Author:
Charlotte Beaudart
Author:
Olivier Bruyère
Author:
Jane A. Cauley
Author:
Peggy M. Cawthon
Author:
Alfonso Jose Cruz-Jentoft
Author:
Kristine Ensrud
Author:
Roger A. Fielding
Author:
Helena Johansson
Author:
John A. Kanis
Author:
Magnus K. Karlsson
Author:
Nancy E. Lane
Author:
Laetitia Lengelé
Author:
Mattias Lorentzon
Author:
Eugene McCloskey
Author:
Dan Mellström
Author:
Anne B. Newman
Author:
Claes Ohlsson
Author:
Eric Orwoll
Author:
Jean Yves Reginster
Author:
Eva Ribom
Author:
Bjorn E. Rosengren
Author:
John T. Schousboe
Author:
Eric J. Shiroma
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics